inflammatory bowel disease

Patients

Driving improved and equitable outcomes for IBD patients acr...

Long-term immunological conditions, including inflammatory bowel disease (IBD), have a significant impact on patients’ lives.

News

AstraZeneca inks $2bn Treg cell therapy deal with Quell

UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which

News

AZ drops IL-23 drug for inflammatory bowel disease

AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in

News

FDA won’t approve Lilly’s mirikizumab for ulcerative colitis

The FDA has issued a complete response letter to Eli Lilly, turning down its attempt to get approval for anti-IL-23p19 antibody mirikizumab as a treatment for ulcerative c

R&D

Into the bowels of gut research

For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge.

News

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).

Driving improved and equitable outcomes for IBD patients acr...

AstraZeneca inks $2bn Treg cell therapy deal with Quell

AZ drops IL-23 drug for inflammatory bowel disease

FDA won’t approve Lilly’s mirikizumab for ulcerative colitis

Into the bowels of gut research

BMS adds to IBD pipeline with $1.9bn GentiBio deal

EMA seeks input on virtual alternative to animal test

Using AI-driven synthetic personas to take your insights fur...

inflammatory bowel disease

Editor's Picks